Chi-An Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chi-An Cheng has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey I. Zink
Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095-1569, USA
10 shared publications - Wei Chen
Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
8 shared publications - David R. Walt
Wyss Institute for Biologically Inspired Engineering, Boston, USA
6 shared publications - Huan-Cheng Chang
Institute of Atomic and Molecular Sciences Academia Sinica Taipei 106 Taiwan
4 shared publications - Yasmeen Senussi
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
4 shared publications - Amy Caryn Sherman
Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts
3 shared publications
Latest Publications
- 29 January 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (5) , 3944-3985
Innovative Lipid-Based Nanobiotechnology: Diagnostics and Medicine
The aim of this review article is to provide a summary of the state-of-the-art technology for the integration of lipid-based natural biomaterials, emphasizing mainly broad applications, especially in therapeutics and diagnostics. Herein, we focused mainly on the utilization of bioengineered lipid-based nanomaterials as medicine and diagnostic agents, which constitute the primary focus of the field of bioengineered lipid-based nanomaterials. Each property of diverse classes of lipid-based nanomaterials is determined by their chemical structure, functionality, and synthesis methodology, and they are versatile for use as drug-delivery nanocarriers, for targeting certain types of cancer cells and for controlled immune therapies. In addition, lipid-based biomaterials have been applied in various research fields with subsequent surface engineering with modulation moieties for the integration of functional nanomaterials (signaling pathway mediators, nucleic acid drugs, and active targeting proteins). The overall manuscript is organized in sections describing materials, fabrication processes, and applications based on innovative lipid-based nanobiotechnology.
- 29 January 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (5) , 3944-3985
Innovative Lipid-Based Nanobiotechnology: Diagnostics and Medicine
The aim of this review article is to provide a summary of the state-of-the-art technology for the integration of lipid-based natural biomaterials, emphasizing mainly broad applications, especially in therapeutics and diagnostics. Herein, we focused mainly on the utilization of bioengineered lipid-based nanomaterials as medicine and diagnostic agents, which constitute the primary focus of the field of bioengineered lipid-based nanomaterials. Each property of diverse classes of lipid-based nanomaterials is determined by their chemical structure, functionality, and synthesis methodology, and they are versatile for use as drug-delivery nanocarriers, for targeting certain types of cancer cells and for controlled immune therapies. In addition, lipid-based biomaterials have been applied in various research fields with subsequent surface engineering with modulation moieties for the integration of functional nanomaterials (signaling pathway mediators, nucleic acid drugs, and active targeting proteins). The overall manuscript is organized in sections describing materials, fabrication processes, and applications based on innovative lipid-based nanobiotechnology.
- 14 October 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (51)
Surface or Luminal? Decoding Tumor Extracellular Vesicle Logic for Functional Insight and Therapeutic Reprogramming
Extracellular vesicles (EVs) hold great promise for diagnostics and therapeutics, but clinical translation is hindered by their heterogeneity and the lack of tools for spatially resolved, subpopulation‐specific functional analysis. Here, the EV bimodal functional regulator (eBFR), an integrated platform combining: (1) CLEAR (Cargo Luminal Elimination to Attenuate Risk) for selective luminal depletion while preserving surface integrity; (2) SWITCHER (SWITCHable EV Releaser) for modular EV subpopulation enrichment; and (3) eSimoa (EV single‐molecule array) for ultrasensitive, compartment‐specific protein quantification. Using tumor‐derived EVs, CLEAR removed pro‐tumor luminal cargo—attenuating their pro‐tumorigenic activity—while preserving preferential uptake by autologous tumor cells, enhancing drug loading by 8430‐fold and improving anticancer efficacy by 37%. Omics‐guided functional assays reveal a spatial “division of labor,” with surface proteins driving uptake and luminal cargo regulating proliferation and migration. These insights inform a 3D EV Functional Decision Matrix linking spatial molecular signatures to phenotypic outcomes. Applied to SARS‐CoV‐2 Spike EVs, eBFR uncovers dose‐, compartment‐, and cell type‐dependent effects, including a “Trojan Horse” mechanism for viral protein transfer and propagation via secondary EVs. eBFR offers a mechanistically informed framework for decoding EV biology, reprogramming vesicle function, and guiding rational design of biosafety‐enhanced, next‐generation EV‐based therapeutics in precision nanomedicine.
- 14 October 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (51)
Surface or Luminal? Decoding Tumor Extracellular Vesicle Logic for Functional Insight and Therapeutic Reprogramming
Extracellular vesicles (EVs) hold great promise for diagnostics and therapeutics, but clinical translation is hindered by their heterogeneity and the lack of tools for spatially resolved, subpopulation‐specific functional analysis. Here, the EV bimodal functional regulator (eBFR), an integrated platform combining: (1) CLEAR (Cargo Luminal Elimination to Attenuate Risk) for selective luminal depletion while preserving surface integrity; (2) SWITCHER (SWITCHable EV Releaser) for modular EV subpopulation enrichment; and (3) eSimoa (EV single‐molecule array) for ultrasensitive, compartment‐specific protein quantification. Using tumor‐derived EVs, CLEAR removed pro‐tumor luminal cargo—attenuating their pro‐tumorigenic activity—while preserving preferential uptake by autologous tumor cells, enhancing drug loading by 8430‐fold and improving anticancer efficacy by 37%. Omics‐guided functional assays reveal a spatial “division of labor,” with surface proteins driving uptake and luminal cargo regulating proliferation and migration. These insights inform a 3D EV Functional Decision Matrix linking spatial molecular signatures to phenotypic outcomes. Applied to SARS‐CoV‐2 Spike EVs, eBFR uncovers dose‐, compartment‐, and cell type‐dependent effects, including a “Trojan Horse” mechanism for viral protein transfer and propagation via secondary EVs. eBFR offers a mechanistically informed framework for decoding EV biology, reprogramming vesicle function, and guiding rational design of biosafety‐enhanced, next‐generation EV‐based therapeutics in precision nanomedicine.
Decoding Complex Biological Milieus: SHINER's Approach to Profiling and Functioning of Extracellular Vesicle Subpopulations
Extracellular vesicles (EVs) are celebrated for their pivotal roles in cellular communication and their potential in disease diagnosis and therapeutic applications. However, their inherent heterogeneity acts as a double‐edged sword, complicating the isolation of specific EV subpopulations. Conventional EV isolation methods often fall short, relying on biophysical properties, while affinity‐based techniques may compromise EV integrity and utility with harsh recovery conditions. To address these limitations, the SHINER (subpopulation homogeneous isolation and nondestructive EV release) workflow is introduced, which redefines how EVs are isolated and recoverd, featuring the innovative SWITCHER (switchable extracellular vesicle releaser) tool. The SHINER workflow facilitates the precise purification and gentle recovery of target EV subpopulations from complex biological mixtures, preserving their structural integrity and biological functionality. Importantly, SHINER demonstrates exceptional adaptability to multiple markers and clinical applications. It not only enhances the ability to trace EV origins for accurate disease diagnosis but also advances fundamental EV research and provides standardized EV materials for therapeutic innovations. By improving the understanding of EVs and enabling the development of personalized diagnostics and treatments, SHINER propels EV‐based science into new frontiers of advanced medicine, offering transformative potential for healthcare.
Decoding Complex Biological Milieus: SHINER's Approach to Profiling and Functioning of Extracellular Vesicle Subpopulations
Extracellular vesicles (EVs) are celebrated for their pivotal roles in cellular communication and their potential in disease diagnosis and therapeutic applications. However, their inherent heterogeneity acts as a double‐edged sword, complicating the isolation of specific EV subpopulations. Conventional EV isolation methods often fall short, relying on biophysical properties, while affinity‐based techniques may compromise EV integrity and utility with harsh recovery conditions. To address these limitations, the SHINER (subpopulation homogeneous isolation and nondestructive EV release) workflow is introduced, which redefines how EVs are isolated and recoverd, featuring the innovative SWITCHER (switchable extracellular vesicle releaser) tool. The SHINER workflow facilitates the precise purification and gentle recovery of target EV subpopulations from complex biological mixtures, preserving their structural integrity and biological functionality. Importantly, SHINER demonstrates exceptional adaptability to multiple markers and clinical applications. It not only enhances the ability to trace EV origins for accurate disease diagnosis but also advances fundamental EV research and provides standardized EV materials for therapeutic innovations. By improving the understanding of EVs and enabling the development of personalized diagnostics and treatments, SHINER propels EV‐based science into new frontiers of advanced medicine, offering transformative potential for healthcare.
- 24 July 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (32) , 14994-15008
Exploring nanodiamonds: leveraging their dual capacities for anticancer photothermal therapy and temperature sensing
Nanodiamond's dual functionality in photothermal therapy combines cancer treatment with precise temperature sensing advantages.
- 24 July 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (32) , 14994-15008
Exploring nanodiamonds: leveraging their dual capacities for anticancer photothermal therapy and temperature sensing
Nanodiamond's dual functionality in photothermal therapy combines cancer treatment with precise temperature sensing advantages.
- Open Access
- 21 May 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (6) , 2625-2636
Before Translating Extracellular Vesicles into Personalized Diagnostics and Therapeutics: What We Could Do
Extracellular vesicle (EV) research is rapidly advancing from fundamental science to translational applications in EV-based personalized therapeutics and diagnostics. Yet, fundamental questions persist regarding EV biology and mechanisms, particularly concerning the heterogeneous interactions between EVs and cells. While we have made strides in understanding virus delivery and intracellular vesicle transport, our comprehension of EV trafficking remains limited. EVs are believed to mediate intercellular communication through cargo transfer, but uncertainties persist regarding the occurrence and quantification of EV-cargo delivery within acceptor cells. This ambiguity is crucial to address, given the significant translational impact of EVs on therapeutics and diagnostics. This perspective article does not seek to provide exhaustive recommendations and guidance on EV-related studies, as these are well-articulated in position papers and statements by the International Society for Extracellular Vesicles (ISEV), including the 'Minimum Information for Studies of Extracellular Vesicles' (MISEV) 2014, MISEV2018, and the recent MISEV2023. Instead, recognizing the multilayered heterogeneity of EVs as both a challenge and an opportunity, this perspective emphasizes novel approaches to facilitate our understanding of diverse EV biology, address uncertainties, and leverage this knowledge to advance EV-based personalized diagnostics and therapeutics. Specifically, this perspective synthesizes current insights, identifies opportunities, and highlights exciting technological advancements in ultrasensitive single EV or "digital" profiling developed within the author's multidisciplinary group. These newly developed technologies address technical gaps in dissecting the molecular contents of EV subsets, contributing to the evolution of EVs as next-generation liquid biopsies for diagnostics and providing better quality control for EV-based therapeutics.
- 21 May 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (6) , 2625-2636
Open AccessBefore Translating Extracellular Vesicles into Personalized Diagnostics and Therapeutics: What We Could Do
Extracellular vesicle (EV) research is rapidly advancing from fundamental science to translational applications in EV-based personalized therapeutics and diagnostics. Yet, fundamental questions persist regarding EV biology and mechanisms, particularly concerning the heterogeneous interactions between EVs and cells. While we have made strides in understanding virus delivery and intracellular vesicle transport, our comprehension of EV trafficking remains limited. EVs are believed to mediate intercellular communication through cargo transfer, but uncertainties persist regarding the occurrence and quantification of EV-cargo delivery within acceptor cells. This ambiguity is crucial to address, given the significant translational impact of EVs on therapeutics and diagnostics. This perspective article does not seek to provide exhaustive recommendations and guidance on EV-related studies, as these are well-articulated in position papers and statements by the International Society for Extracellular Vesicles (ISEV), including the 'Minimum Information for Studies of Extracellular Vesicles' (MISEV) 2014, MISEV2018, and the recent MISEV2023. Instead, recognizing the multilayered heterogeneity of EVs as both a challenge and an opportunity, this perspective emphasizes novel approaches to facilitate our understanding of diverse EV biology, address uncertainties, and leverage this knowledge to advance EV-based personalized diagnostics and therapeutics. Specifically, this perspective synthesizes current insights, identifies opportunities, and highlights exciting technological advancements in ultrasensitive single EV or "digital" profiling developed within the author's multidisciplinary group. These newly developed technologies address technical gaps in dissecting the molecular contents of EV subsets, contributing to the evolution of EVs as next-generation liquid biopsies for diagnostics and providing better quality control for EV-based therapeutics.
- Open Access
- 20 November 2023
- Published by Wiley in Advanced Science
- Vol. 11 (3) , e2304926
Ultrasensitive and High‐Resolution Protein Spatially Decoding Framework for Tumor Extracellular Vesicles
Proteins localized on the surface or within the lumen of tumor‐derived extracellular vesicles (EVs) play distinct roles in cancer progression. However, quantifying both populations of proteins within EVs has been hampered due to the limited sensitivity of the existing protein detection methods and inefficient EV isolation techniques. In this study, the eSimoa framework, an innovative approach enabling spatial decoding of EV protein biomarkers with unmatched sensitivity and specificity is presented. Using the luminal eSimoa pipeline, the absolute concentration of luminal RAS or KRASG12D proteins is released and measured, uncovering their prevalence in pancreatic tumor‐derived EVs. The pulldown eSimoa pipeline measured absolute protein concentrations from low‐abundance EV subpopulations. The eSimoa assays detected EVs in both PBS and plasma samples, confirming their applicability across diverse clinical sample types. Overall, the eSimoa framework offers a valuable tool to (1) detect EVs at concentrations as low as 105 EV mL−1 in plasma, (2) quantify absolute EV protein concentrations as low as fM, and (3) decode the spatial distribution of EV proteins. This study highlights the potential of eSimoa in identifying disease‐specific EV protein biomarkers in clinical samples with minimal pre‐purification, thereby driving advancements in clinical translation.
- 20 November 2023
- Published by Wiley in Advanced Science
- Vol. 11 (3) , e2304926
Open AccessUltrasensitive and High‐Resolution Protein Spatially Decoding Framework for Tumor Extracellular Vesicles
Proteins localized on the surface or within the lumen of tumor‐derived extracellular vesicles (EVs) play distinct roles in cancer progression. However, quantifying both populations of proteins within EVs has been hampered due to the limited sensitivity of the existing protein detection methods and inefficient EV isolation techniques. In this study, the eSimoa framework, an innovative approach enabling spatial decoding of EV protein biomarkers with unmatched sensitivity and specificity is presented. Using the luminal eSimoa pipeline, the absolute concentration of luminal RAS or KRASG12D proteins is released and measured, uncovering their prevalence in pancreatic tumor‐derived EVs. The pulldown eSimoa pipeline measured absolute protein concentrations from low‐abundance EV subpopulations. The eSimoa assays detected EVs in both PBS and plasma samples, confirming their applicability across diverse clinical sample types. Overall, the eSimoa framework offers a valuable tool to (1) detect EVs at concentrations as low as 105 EV mL−1 in plasma, (2) quantify absolute EV protein concentrations as low as fM, and (3) decode the spatial distribution of EV proteins. This study highlights the potential of eSimoa in identifying disease‐specific EV protein biomarkers in clinical samples with minimal pre‐purification, thereby driving advancements in clinical translation.
- Open Access
- 9 May 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (21) , 14685-14697
Integrated pipeline for ultrasensitive protein detection in cancer nanomedicine
We have developed an integrated pipeline called nanoSimoa that combines an ultrasensitive protein detection technique (Simoa) with cancer nanomedicine, providing an adequate understanding of the nanomedicine's mechanism of action.
- 9 May 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (21) , 14685-14697
Open AccessIntegrated pipeline for ultrasensitive protein detection in cancer nanomedicine
We have developed an integrated pipeline called nanoSimoa that combines an ultrasensitive protein detection technique (Simoa) with cancer nanomedicine, providing an adequate understanding of the nanomedicine's mechanism of action.
- Top Cited Papers
- 14 March 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (11) , 867-876
Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis
Background: Cases of adolescents and young adults developing myocarditis after vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–targeted mRNA vaccines have been reported globally, but the underlying immunoprofiles of these individuals have not been described in detail. Methods: From January 2021 through February 2022, we prospectively collected blood from 16 patients who were hospitalized at Massachusetts General for Children or Boston Children’s Hospital for myocarditis, presenting with chest pain with elevated cardiac troponin T after SARS-CoV-2 vaccination. We performed extensive antibody profiling, including tests for SARS-CoV-2–specific humoral responses and assessment for autoantibodies or antibodies against the human-relevant virome, SARS-CoV-2–specific T-cell analysis, and cytokine and SARS-CoV-2 antigen profiling. Results were compared with those from 45 healthy, asymptomatic, age-matched vaccinated control subjects. Results: Extensive antibody profiling and T-cell responses in the individuals who developed postvaccine myocarditis were essentially indistinguishable from those of vaccinated control subjects, despite a modest increase in cytokine production. A notable finding was that markedly elevated levels of full-length spike protein (33.9±22.4 pg/mL), unbound by antibodies, were detected in the plasma of individuals with postvaccine myocarditis, whereas no free spike was detected in asymptomatic vaccinated control subjects (unpaired t test; P <0.0001). Conclusions: Immunoprofiling of vaccinated adolescents and young adults revealed that the mRNA vaccine–induced immune responses did not differ between individuals who developed myocarditis and individuals who did not. However, free spike antigen was detected in the blood of adolescents and young adults who developed post-mRNA vaccine myocarditis, advancing insight into its potential underlying cause.
- 14 March 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (11) , 867-876
Top Cited PapersCirculating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis
Background: Cases of adolescents and young adults developing myocarditis after vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–targeted mRNA vaccines have been reported globally, but the underlying immunoprofiles of these individuals have not been described in detail. Methods: From January 2021 through February 2022, we prospectively collected blood from 16 patients who were hospitalized at Massachusetts General for Children or Boston Children’s Hospital for myocarditis, presenting with chest pain with elevated cardiac troponin T after SARS-CoV-2 vaccination. We performed extensive antibody profiling, including tests for SARS-CoV-2–specific humoral responses and assessment for autoantibodies or antibodies against the human-relevant virome, SARS-CoV-2–specific T-cell analysis, and cytokine and SARS-CoV-2 antigen profiling. Results were compared with those from 45 healthy, asymptomatic, age-matched vaccinated control subjects. Results: Extensive antibody profiling and T-cell responses in the individuals who developed postvaccine myocarditis were essentially indistinguishable from those of vaccinated control subjects, despite a modest increase in cytokine production. A notable finding was that markedly elevated levels of full-length spike protein (33.9±22.4 pg/mL), unbound by antibodies, were detected in the plasma of individuals with postvaccine myocarditis, whereas no free spike was detected in asymptomatic vaccinated control subjects (unpaired t test; P <0.0001). Conclusions: Immunoprofiling of vaccinated adolescents and young adults revealed that the mRNA vaccine–induced immune responses did not differ between individuals who developed myocarditis and individuals who did not. However, free spike antigen was detected in the blood of adolescents and young adults who developed post-mRNA vaccine myocarditis, advancing insight into its potential underlying cause.
- Open Access
- 1 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 337.e1-337.e5
Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation
- 1 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 337.e1-337.e5
Open AccessImpact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation